NextCure Inc (NXTC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.82-0.26%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NXTC
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Finalize the all-stock merger with Avere Therapeutics, including closing conditions and stockholder approvals, to combine operations and trade as Avere Therapeutics.
Stated as a priority in 2 quarters including 2026-Q2 and a July 2026 press release. The merger agreement with Avere Therapeutics was announced with expected closing in the second half of 2026. The company is actively preserving capital and restructuring in support of this transaction. The trajectory is delivering as the merger remains on track for completion within the stated timeframe.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Announced definitive merger agreement with Avere Therapeutics in an all-stock transaction, expected to close in second half of 2026.”
Progress SIM0505 antibody-drug conjugate clinical development including Phase 1 dose escalation, dose optimization, and data readouts with focus on gynecologic cancers.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and a June 2026 ASCO presentation. SIM0505 achieved a 55% objective response rate in gynecologic cancers in Phase 1 dose escalation. Dose optimization initiated with plans to expand trial sites, though in 2026-Q2 the company ceased expansion into Europe and Canada. The trajectory shows active clinical progress with some strategic adjustments.
“Initiated efforts to preserve value of SIM0505 and current clinical assets; no expansion of clinical site footprint into Europe and Canada.”
“SIM0505 Phase 1 dose escalation data expected in Q2 2026; dose optimization initiated; plans to increase trial sites including Canada and Europe.”
Maintain sufficient cash, cash equivalents, and marketable securities to fund planned operations and capital expenditures into the first half of 2027.
Stated as a priority in 4 quarters from 2025-Q3 through 2026-Q2. Cash and equivalents declined from $41.8 million at 2025-Q4 to $20.1 million at 2026-Q2, reflecting cash used in operations. Management consistently stated that current financial resources are sufficient to fund operations into the first half of 2027. The trajectory shows active capital preservation amid ongoing operational cash burn.
“Preserving capital in support of merger closing; cash, cash equivalents, and marketable securities were $20.1 million as of June 30, 2026.”
“Cash, cash equivalents, and marketable securities were $29.7 million as of March 31, 2026; resources sufficient to fund operating expenses and capex into first half of 2027.”
“Expect current financial resources to be sufficient to fund operating expenses and capital expenditures into mid-2026.”
“Expect current financial resources to be sufficient to fund operating expenses and capital expenditures into mid-2026.”
Implement restructuring initiatives including workforce reduction, facility footprint reduction, and asset sales to reduce operating expenses ahead of merger completion.
Stated as a priority in 2 quarters including 2026-Q2 and a July 2026 announcement. The company initiated workforce reductions and facility footprint downsizing, incurring $5.1 million in asset impairment costs in 2026-Q2. Operating loss improved from -$27.3 million in 2025-Q2 to -$15.1 million in 2026-Q2, indicating progress in expense reduction. The trajectory shows delivering on cost reduction through restructuring.
“Advanced restructuring initiatives to reduce operating expenses, including facility footprint reductions and asset sales in preparation for merger.”
Maintain sufficient financial resources to fund operating expenses and capital expenditures into the first half of 2027.
Over the trailing year it converted 0.95x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
16 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.